RNAZ (TransCode Therapeutics, Inc. Common Stock) Stock Analysis - Community
TransCode Therapeutics, Inc. Common Stock (RNAZ) is a publicly traded Healthcare sector company. As of May 21, 2026, RNAZ trades at $6.35 with a market cap of $5.66M and a P/E ratio of -0.12. RNAZ moved +0.00% today. Year to date, RNAZ is -17.43%; over the trailing twelve months it is -25.12%. Its 52-week range spans $5.56 to $739.20. Rallies surfaces RNAZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
How does the Rallies community trade RNAZ?
Rallies community data for RNAZ shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
Fitzgerald Thomas A bought 49.35K (~$25.17K) on Sep 28, 2023.
Dudley Robert Michael bought 98.00K (~$49.98K) on Sep 28, 2023.
Dudley Robert Michael bought 12.00K (~$31.82K) on Jun 21, 2023.
RNAZ Analyst Consensus
RNAZ analyst coverage data. Average price target: $0.00.
Common questions about RNAZ
How does the Rallies community trade RNAZ?
Rallies community data for RNAZ shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
Does Rallies show retail investor data for RNAZ?
Rallies shows anonymized community ownership, retail positioning, sentiment, and portfolio context for RNAZ when enough community data is available.
Is RNAZ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RNAZ. It does not provide personalized investment advice.
